Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 4
1992 6
1993 50
1994 67
1995 81
1996 104
1997 129
1998 116
1999 116
2000 100
2001 87
2002 99
2003 125
2004 83
2005 112
2006 111
2007 98
2008 94
2009 120
2010 115
2011 114
2012 113
2013 125
2014 123
2015 152
2016 138
2017 147
2018 155
2019 161
2020 147
2021 144
2022 108
2023 87
2024 50

Text availability

Article attribute

Article type

Publication date

Search Results

3,224 results

Results by year

Filters applied: . Clear all
Page 1
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell MA, Zweizig SL, Warshal DP, Hanjani P, Carney ME, Huang H, Cella D, Zaino R, Fleming GF. Miller DS, et al. J Clin Oncol. 2020 Nov 20;38(33):3841-3850. doi: 10.1200/JCO.20.01076. Epub 2020 Sep 29. J Clin Oncol. 2020. PMID: 33078978 Free PMC article. Clinical Trial.
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO; American Society of Clinical Oncology. Smith TJ, et al. J Clin Oncol. 2015 Oct 1;33(28):3199-212. doi: 10.1200/JCO.2015.62.3488. Epub 2015 Jul 13. J Clin Oncol. 2015. PMID: 26169616 Review.
RESULTS: Changes to previous recommendations include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the recommendation regarding routine use of CSFs in older patients with diffuse aggressive lymphoma, and addition of recommendations against routin …
RESULTS: Changes to previous recommendations include the addition of tbo-filgrastim and filgrastim-sndz, moderation of the rec …
A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, Morrow PK, Allcott K, Lyman GH. Dale DC, et al. Support Care Cancer. 2018 Jan;26(1):7-20. doi: 10.1007/s00520-017-3854-x. Epub 2017 Sep 22. Support Care Cancer. 2018. PMID: 28939926 Free PMC article. Review.
PURPOSE: Filgrastim (NEUPOGEN()) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing neutropenia-related infections and mobilizing hematopoietic stem cells. ...CONCLUSIONS: This systematic literature review and meta-analysis …
PURPOSE: Filgrastim (NEUPOGEN()) is the originator recombinant human granulocyte colony-stimulating factor widely used for preventing …
Motixafortide: First Approval.
Hoy SM. Hoy SM. Drugs. 2023 Nov;83(17):1635-1643. doi: 10.1007/s40265-023-01962-w. Drugs. 2023. PMID: 37996648 Review.
On 11 September 2023, motixafortide was approved in the USA for use in combination with filgrastim [granulocyte colony stimulating factor (G-CSF)] to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple my …
On 11 September 2023, motixafortide was approved in the USA for use in combination with filgrastim [granulocyte colony stimulating fa …
Filgrastim induced thrombocytopenia.
Kango G, Haroun F. Kango G, et al. BMJ Case Rep. 2020 Jun 30;13(6):e234584. doi: 10.1136/bcr-2020-234584. BMJ Case Rep. 2020. PMID: 32606115 Free PMC article.
The diagnosis is ascertained when there is reproducibility of thrombocytopenia with repeated exposure. Filgrastim is used during peripheral blood progenitor cell harvest during autologous stem cell transplantation in the setting of multiple myeloma to prolong event-free su …
The diagnosis is ascertained when there is reproducibility of thrombocytopenia with repeated exposure. Filgrastim is used during peri …
Zarxio--a filgrastim biosimilar.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2016 Mar 14;58(1490):34-5. Med Lett Drugs Ther. 2016. PMID: 26963154 Review. No abstract available.
Tbo-Filgrastim: A Review in Neutropenic Conditions.
Blair HA, Scott LJ. Blair HA, et al. BioDrugs. 2016 Apr;30(2):153-60. doi: 10.1007/s40259-016-0172-7. BioDrugs. 2016. PMID: 27023705 Review.
Tbo-filgrastim was generally well tolerated, with a similar safety profile to that of reference filgrastim. ...Current evidence indicates that tbo-filgrastim is a useful alternative to reference filgrastim in patients requiring filgrastim therap …
Tbo-filgrastim was generally well tolerated, with a similar safety profile to that of reference filgrastim. ...Current evidenc …
Filgrastim, fibrinolysis, and neovascularization.
Eton D, Zhou G, He TC, Bartholomew A, Patil R. Eton D, et al. J Tissue Eng Regen Med. 2022 May;16(5):496-510. doi: 10.1002/term.3284. Epub 2022 Feb 17. J Tissue Eng Regen Med. 2022. PMID: 35175691 Free PMC article.
In the PCP-alone group, blood was sampled on Day 1 (baseline) and after 30 days of daily PCP. In the Filgrastim and PCP group, blood was drawn on Day 1, and 1 day after the 5th and the 10th Filgrastim doses. ...Filgrastim at this novel dosimetry induced fibri …
In the PCP-alone group, blood was sampled on Day 1 (baseline) and after 30 days of daily PCP. In the Filgrastim and PCP group, blood …
The evolution of value with filgrastim in oncology.
Cornes P, Krendyukov A. Cornes P, et al. Future Oncol. 2019 May;15(13):1525-1533. doi: 10.2217/fon-2018-0762. Epub 2019 Mar 5. Future Oncol. 2019. PMID: 30835142 Review.
The recombinant G-CSF filgrastim was first approved in 1991, and its value has been evolving ever since. ...However, more recent meta-analyses of placebo-controlled randomized trial data show falling costs due to biosimilar competition and absolute overall survival gains o …
The recombinant G-CSF filgrastim was first approved in 1991, and its value has been evolving ever since. ...However, more recent meta …
Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.
Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J, Jiang M, Bai H, Lang T, Wang J, Liu L, Yang T, Huang X, Liu F, Lou S, Liu Y, Zhang C, Liu H, Gao L, Liu J, Zhu L, Wen Q, Chen T, Wang P, Rao J, Mao M, Wang C, Duan X, Luo L, Peng X, Cassady K, Zhong JF, Zhang X. Gao L, et al. J Clin Oncol. 2020 Dec 20;38(36):4249-4259. doi: 10.1200/JCO.19.03277. Epub 2020 Oct 27. J Clin Oncol. 2020. PMID: 33108244 Free PMC article. Clinical Trial.
3,224 results